

October 7, 2008

Article Published in the American Journal of Clinical Oncology Shows Medipattern's B-CAD® Increases Diagnostic Accuracy on Small Breast Cancer Lesions
B-CAD V2 shown to increase diagnostic accuracy by 44%

TORONTO, ONTARIO--(Marketwire - Oct. 7, 2008) -

The Medipattern Corporation (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announce that a study abstract, showing a statistically significant increase in diagnostic accuracy when using B-CAD Version 2 on lesions less than 1 cm in size, has been published in the October 2008 issue of the American Journal of Clinical Oncology.

The study was conducted at the PLA301 Hospital in Beijing, China using the global version of B-CAD Version 2, and reported in the paper: "The Value of Computer-Aided Detection for Breast Ultra-Sonography (B-CAD) in the Diagnosis of Breast Cancer" by principal authors Dr. Jun Lai Li and Dr. Dan Fei Song. The study is based upon 100 confirmed biopsied cases, comparing the diagnostic accuracy of three reading scenarios: a single physician, double reading with two physicians, and a single physician reading with B-CAD. The accuracy of the single physician increased with B-CAD in all categories. The most striking result shows a statistically significant 44 percent improvement in diagnostic accuracy for the single reader with B-CAD V2 on lesions less than 1 cm in size (n equals 9).

"Finding small cancers is a particularly important part of our overall goal to find cancer in its earliest stage while it is still treatable. Yet small cancers present doctors with their greatest challenge as it is one of the main reasons for misdiagnosis. B-CAD can assist doctors in focusing on these easily overlooked important details and increase the detection rate of small breast cancers," notes Dr. Li in the paper. "The study also finds that CAD is a very useful tool for China's current needs; a single doctor with B-CAD can perform as well as two doctors reading together. A single doctor with B-CAD is far more efficient and economical than using our limited skilled resources for double reading."

"We are very honoured that the authors considered CAD a worthy topic for investigation. The results demonstrate the value of B-CAD V2 in making doctors more efficient, more productive and more effective in the diagnosis of breast cancer," stated Jeff Collins, president and CEO of Medipattern. "These results were first shared during NCBC earlier this year. Publication in a major medical journal is a great honour for all of the authors. It further validates that the study was planned and executed with precision; and that the results increase medical understanding - globally. All of us at Medipattern congratulate the authors on their accomplishment. B-CAD V2 is currently available globally outside of the United States and has received Chinese SFDA as well as CE-medical in Europe and of course Canadian CMDCAS."